Skip to main content
85 search results for:

EULAR 2020 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. play
    10-06-2020 | EULAR 2020 | Conference coverage | Video

    EULAR 2020 highlights: Oliver FitzGerald

    Oliver FitzGerald outlines his highlights from the psoriatic arthritis presentations at the EULAR 2020 E-Congress, and discusses what the study results mean for clinical practice (10:13).

  2. play
    12-06-2020 | EULAR 2020 | Conference coverage | Video

    EULAR 2020 highlights: Fernando Pérez-Ruiz

    Fernando Pérez-Ruiz discusses some of the key gout and crystal arthritis studies presented at the EULAR 2020 E-Congress (8:10).

  3. 12-05-2020 | EULAR 2020 | Conference coverage | Channel

    EULAR 2020 E-Congress

    EULAR 2020 E-Congress news on key clinical trials in rheumatology, including SELECT-CHOICE, EXCEED, JAK-pot, and BLISS-LN studies.

  4. 30-08-2022 | COVID-19 | News | Article

    Studies bolster evidence for COVID-19 vaccination in young people with RMDs

    Vaccination well tolerated in patients with Kawasaki disease The final study used electronic medical records from 2020–2022 to describe the safety outcomes of 153 patients with Kawasaki disease (KD) aged an average of 13 years (range 5–21 years) who received at least one dose of an mRNA COVID-19 vaccine, primarily the Pfizer–BioNTech vaccine (93.5%).

  5. 03-06-2022 | EULAR 2022 | Conference coverage | Article

    ​​​​​​​The EULAR 2022 Debate: Will COVID-19 have a long-term impact on rheumatology practice?

    At the EULAR 2022 Congress in Copenhagen, Denmark, two experts debated whether COVID-19 will have a lasting effect on rheumatology clinical practice.

  6. 28-02-2022 | COVID-19 | News | Article
    News in brief

    SLE disease activity, glucocorticoid use linked to more severe COVID-19 outcomes

    A total of 1606 individuals with SLE and COVID-19 who were included in the GRA or EULAR COVID-19 registries between March 2020 and June 2021 were categorized into four groups of COVID-19 severity.

  7. 18-01-2022 | COVID-19 | Feature | Article

    COVID-19: Lessons learned for rheumatology practice

    How has the pandemic changed clinical practice and what learnings can rheumatologists take forward to improve patient care?

    Indeed, the COVID-19 Global Rheumatology Alliance was established on March 12, 2020 – the day after the World Health Organization declared the COVID-19 outbreak a pandemic – with the aim of collecting, analyzing, and disseminating information to improve the care of patents with rheumatic diseases.

  8. 07-11-2021 | ACR 2021 | Conference coverage | Article

    High rates of severe COVID-19 in patients with vasculitis, polymyalgia rheumatica

    An analysis of data from the COVID-19 Global Rheumatology Alliance and EULAR COVID-19 registries suggests high rates of severe COVID-19 among people with primary systemic vasculitis or polymyalgia rheumatica.

  9. 21-02-2019 | Spondyloarthropathies | Feature | Article
    Updated June 2022

    Trials of JAK inhibitors in spondyloarthritis: A round-up

    Related news story:   Upadacitinib shows promise for PsA SELECT-PsA 2 Phase 3 Patient population: Moderate-to-severe PsA and an inadequate response to at least one biologic DMARD Treatment groups: Upadacitinib 15 mg or 30 mg/day, or placebo Status: Results reported https://clinicaltrials.gov/ct2/show/NCT03104374 Also reported at the EULAR 2020 E-Congress, SELECT-PsA-2 demonstrated significantly higher ACR20 response rates at week 12 among patients treated with upadacitinib 15 mg or 30 mg versus placebo (57 and 64 vs 24%).

  10. 07-06-2021 | EULAR 2021 | Conference coverage | Article

    Real-world studies point to similar effectiveness of JAK inhibitors and biologics

    Findings from two real-world studies presented at the EULAR 2021 Virtual Congress suggest that JAK inhibitors and biologics are similarly effective for the treatment of inflammatory arthritis.

  11. 02-06-2021 | EULAR 2021 | Conference coverage | Article

    ​​​​​​​Rituximab, JAK inhibitors linked to worse COVID-19 severity in RA patients

    The study, which was presented at the EULAR 2021 Virtual congress and published in the Annals of the Rheumatic Diseases , included 2869 RA patients (mean age 57 years, 81% women) treated with biologics or targeted synthetic DMARDs at the time of COVID-19 onset who were entered into the C19-GRA registry between March 2020 and April 2021.

  12. 05-06-2021 | EULAR 2021 | Conference coverage | Article

    Pfizer–BioNTech vaccine immunogenicity confirmed in patients with AIIRDs

    EULAR 2021 Virtual Congress; 2–5 June

  13. 05-06-2020 | EULAR 2020 | Conference coverage | Article

    Phase 3 results ADVOCATE C5a receptor inhibition for ANCA-associated vasculitis

    Serious infections were reported in 13.3% and 15.2% of patients, respectively, and a corresponding 66.3% and 80.5% had AEs judged by the investigators to be potentially related to glucocorticoids. m edwireNews is an independent medical news service provided by Springer Healthcare. © 2020 Springer Healthcare part of the Springer Nature Group EULAR 2020 E-Congress; 3–6 Jun Ann Rheum Dis 2020; doi:10.1136/annrheumdis-2020-eular.1073

  14. 07-05-2021 | Gout | Feature | Article

    Febuxostat and cardiovascular risk in people with gout

    However, in 2020 the European FAST trial  found no increased risk for CV events, mortality, or serious adverse events among patients treated with febuxostat compared with allopurinol.

  15. 07-09-2018 | Treatment | Feature | Article

    At a glance: Common scores used in rheumatology

    Link to further information: https://www.rheumatology.org/Portals/0/Files/ACR_Core_Disease_Activity_RA_Clinical_Trials93.pdf EULAR response European League Against Rheumatism response criteria Definition: Response criteria based on the DAS28 index.

  16. 10-02-2021 | COVID-19 | News | Article
    News in brief

    EULAR issues ‘points to consider’ on immunomodulatory treatment for COVID-19

    EULAR has issued guidance on the pathophysiology of COVID-19 and the potential use of immunomodulatory therapies for its treatment.

  17. 06-06-2020 | EULAR 2020 | Conference coverage | Article

    COVID-19 hospitalization: What do the data tell us?

    There were a variety of sessions at the EULAR 2020 E-Congress talking about the risk factors associated with COVID-19 hospitalization among patients with rheumatic conditions, as data from the COVID-19 Global Rheumatology Alliance registry and contributing national registries become available.

  18. 18-11-2020 | COVID-19 | Feature | Article

    Telemedicine in rheumatology: COVID-19 and beyond

    For instance, at the time of writing EULAR recommends that consultations can take place remotely and blood monitoring can be postponed temporarily, provided that the RMD and treatment are stable and there are no signs or symptoms of drug toxicity.

  19. 10-12-2020 | Rheumatoid arthritis | News | Article

    Combining QRISK3 and EULAR mSCORE may optimize CV risk prediction in RA

    Combining the QRISK3 and the EULAR modified systematic coronary risk evaluation algorithms may optimize identification of people with rheumatoid arthritis at high risk for carotid plaques, research suggests.

  20. 27-11-2020 | Sjögren’s syndrome | News | Article
    News in brief

    No clinical benefit of abatacept in primary Sjögren’s syndrome

    Mean changes in EULAR Sjögren’s Syndrome Patient Reported Index and stimulated whole salivary flow were also comparable in the two groups.

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.